In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are Fund Managers Shunning European Biotech?

Executive Summary

Despite some recent successes, European biotech remains a less attractive investment opportunity than US biotech, according to most of the panel of European-based health care fund managers interviewed by In Vivo Europe Rx. But all is not lost: some running Europe-only, specialist funds continue to see value in the early stage small-caps.

You may also be interested in...

OncoMethylome Sciences SA

Epigenomics AG may be a big name in the small world of diagnostic start-ups these days because of its recent IPO, but two-year-old OncoMethylome Sciences SA believes it can give the older company stiff competition in the emerging field of DNA methylation-based cancer markers. The company is developing tests for early diagnosis of cancer and stratification of disease treatments, using highly sensitive, cost-effective DNA methylation technologies.

Chiron/PowderJect: US Snaps Up Europe's Best

Chiron's acquisition of PowderJect is the most recent sign that the vaccines industry is coming of age, taking the field's only two mid-sized players up among the top-ranking Big Pharma. This deal was largely about infrastructure. But it suggests any European biotech with a valuable asset--be it product or distribution network--is an attractive takeover target for US firms.

Working Around Pre-Emption Rights

Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts